PE20091080A1 - 2-[3-(2,2-difluoro-benzo[1,3]dioxol-5-ilamino)-5-(2,6-dimetil-piridin-4-il)-[1,2,4]triazol-1-il]-n-etil-acetamida y sus sales como moduladores de los receptores nicotinicos alfa 7 - Google Patents

2-[3-(2,2-difluoro-benzo[1,3]dioxol-5-ilamino)-5-(2,6-dimetil-piridin-4-il)-[1,2,4]triazol-1-il]-n-etil-acetamida y sus sales como moduladores de los receptores nicotinicos alfa 7

Info

Publication number
PE20091080A1
PE20091080A1 PE2008001789A PE2008001789A PE20091080A1 PE 20091080 A1 PE20091080 A1 PE 20091080A1 PE 2008001789 A PE2008001789 A PE 2008001789A PE 2008001789 A PE2008001789 A PE 2008001789A PE 20091080 A1 PE20091080 A1 PE 20091080A1
Authority
PE
Peru
Prior art keywords
ilamino
dioxol
triazol
difluoro
pyridin
Prior art date
Application number
PE2008001789A
Other languages
English (en)
Inventor
Johannes Wilhelmus John F Thuring
Theodorus Dinklo
Anne Simone Josephine Lesage
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20091080A1 publication Critical patent/PE20091080A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA AL COMPUESTO 2-[3-(2,2-DIFLUORO-BENZO[1,3]DIOXOL-5-ILAMINO)-5-(2,6-DIMETIL-PIRIDIN-4-IL)-[1,2,4]TRIAZOL-1-IL]-N-ETIL-ACETAMIDA DE FORMULA (I), SALES, HIDRATOS Y SOLVATOS DEL MISMO. TAMBIEN ESTA REFERIDA A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES MODULADOR ALOSTERICO POSITIVO DE LOS RECEPTORES NICOTINICOS ALFA 7 DE ACETILCOLINA Y SON UTILES EN EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER, DEMENCIA DEL CUERPO DE LEWY, ENFERMEDAD DE PARKINSON, ENTRE OTRAS
PE2008001789A 2007-10-18 2008-10-17 2-[3-(2,2-difluoro-benzo[1,3]dioxol-5-ilamino)-5-(2,6-dimetil-piridin-4-il)-[1,2,4]triazol-1-il]-n-etil-acetamida y sus sales como moduladores de los receptores nicotinicos alfa 7 PE20091080A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07118822 2007-10-18

Publications (1)

Publication Number Publication Date
PE20091080A1 true PE20091080A1 (es) 2009-08-03

Family

ID=39047591

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001789A PE20091080A1 (es) 2007-10-18 2008-10-17 2-[3-(2,2-difluoro-benzo[1,3]dioxol-5-ilamino)-5-(2,6-dimetil-piridin-4-il)-[1,2,4]triazol-1-il]-n-etil-acetamida y sus sales como moduladores de los receptores nicotinicos alfa 7

Country Status (18)

Country Link
US (1) US8404851B2 (es)
EP (1) EP2205594B1 (es)
JP (1) JP2011500624A (es)
CN (1) CN101827839B (es)
AR (1) AR068919A1 (es)
AT (1) ATE522523T1 (es)
AU (1) AU2008313775B2 (es)
CA (1) CA2697982C (es)
CL (1) CL2008003067A1 (es)
ES (1) ES2371863T3 (es)
IL (1) IL205102A (es)
JO (1) JO2784B1 (es)
MX (1) MX2010004176A (es)
PA (1) PA8799901A1 (es)
PE (1) PE20091080A1 (es)
RU (1) RU2476433C2 (es)
TW (1) TW200934491A (es)
WO (1) WO2009050185A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410087B2 (en) * 2006-10-19 2013-04-02 Takeda Pharmaceutical Company Limited Indole compound
ES2424023T3 (es) * 2007-10-18 2013-09-26 Janssen Pharmaceutica N.V. 1,2,4-triazoles trisustituidos
CN102066343B (zh) * 2008-03-19 2013-12-04 詹森药业有限公司 作为烟碱乙酰胆碱受体调节剂的三取代1，2，4-三唑类
WO2009135944A1 (en) * 2008-05-09 2009-11-12 Janssen Pharmaceutica Nv Trisubstituted pyrazoles as acetylcholine receptor modulators
WO2012104782A1 (en) 2011-02-03 2012-08-09 Lupin Limited Pyrrole derivatives used as modulators of alpha7 nachr
ES2594409T3 (es) 2011-02-23 2016-12-20 Lupin Limited Derivados de heteroarilo como moduladores del nAChR á7
KR101851140B1 (ko) 2011-02-25 2018-04-23 얀센 파마슈티카 엔.브이. 알파 7 nAChR의 알로스테릭 조절자로서의 (피리딘-4-일)벤질아미드
BR112013025128A2 (pt) 2011-03-31 2017-02-14 Lupin Ltd derivados de pirrol como moduladores de receptor de acetilcolina nicotínico para uso no tratamento de distúrbios neurodegenenerativos tal como doença de alzheimer e doença de parkinson
WO2013005153A1 (en) 2011-07-05 2013-01-10 Lupin Limited Biaryl derivatives as nachr modulators
IN2014MN01756A (es) 2012-03-06 2015-07-03 Lupin Ltd
US20150299178A1 (en) 2012-11-12 2015-10-22 Lupin Limited Thiazole Derivatives as Alpha 7 NACHR Modulators
WO2014111839A1 (en) 2013-01-16 2014-07-24 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators
JP2016512225A (ja) 2013-03-13 2016-04-25 ルピン・リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ アルファー７ｎａｃｈｒモジュレータとしてのピロール誘導体
TW201446243A (zh) 2013-06-03 2014-12-16 Lupin Ltd 4-(5-(4-氯苯基)-2-(2-環丙基乙醯基)-1,4-二甲基-1氫-吡咯-3-基)苯磺醯胺作為α7尼古丁乙醯膽鹼受體調節劑
WO2014203150A1 (en) 2013-06-17 2014-12-24 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795907A (fr) * 1972-02-25 1973-06-18 Luso Farmaco Inst 2-amino-4-arylthiazoles 5-substitues et leur preparation
DE3773746D1 (en) 1986-05-07 1991-11-21 Fisons Plc Pyrazole.
JPS6339868A (ja) 1986-08-04 1988-02-20 Otsuka Pharmaceut Factory Inc ジ低級アルキルフエノ−ル誘導体
US4761422A (en) 1986-11-20 1988-08-02 Lusofarmaco Istituto Lusofarmaco D'italia Spa (2-amino-4-aryl-thiazole-5-yl)ethanols and their derivatives having diuretic activity and methods for preparing the same
JPH10504542A (ja) 1994-07-27 1998-05-06 ジー．ディー．サール アンド カンパニー 炎症処置用の置換チアゾール化合物
MX9702380A (es) 1995-08-02 1998-02-28 Uriach & Cia Sa J Nuevas carboxamidas con actividad antifungica.
FR2754258B1 (fr) 1996-10-08 1998-12-31 Sanofi Sa Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
US6187797B1 (en) * 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
ATE236890T1 (de) 1996-12-23 2003-04-15 Bristol Myers Squibb Pharma Co Sauerstoff oder schwefel enthaltende 5-gliedrige heteroaromatishe derivative als factor xa hemmer
DE69821132T2 (de) 1997-10-27 2004-10-21 Takeda Chemical Industries Ltd 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
FR2792314B1 (fr) 1999-04-15 2001-06-01 Adir Nouveaux composes aminotriazoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PT1070708E (pt) 1999-07-21 2004-05-31 Hoffmann La Roche Derivados de triazol
CA2381215A1 (en) 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. P38map kinase inhibitors
FR2802530B1 (fr) 1999-12-17 2002-02-22 Sanofi Synthelabo Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2,4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant
US7105550B2 (en) 2000-03-01 2006-09-12 Christopher Love 2,4-disubstituted thiazolyl derivatives
AU2001249670A1 (en) 2000-04-03 2001-10-15 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activatorinhibitor-1
EP1320365A4 (en) 2000-09-21 2004-03-17 Bristol Myers Squibb Co SUBSTITUTED AZOLE DERIVATIVES AS AN INHIBITOR OF THE CORTICOTROPIN RELEASE FACTOR
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
YU51803A (sh) 2000-12-22 2006-05-25 Ortho Mc Neil Pharmaceutical Inc. Supstituisani derivati triazol diamina kao inhibitori kinaza
US7232838B2 (en) 2001-08-13 2007-06-19 Janssen Pharmaceutica N.V. 2-amino-4,5-trisubstituted thiazolyl derivatives
US20050004134A1 (en) * 2001-11-08 2005-01-06 Hideo Tsutsumi Thiazole derivative and pharmaceutical use thereof
EP1467981A1 (en) 2002-01-25 2004-10-20 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
DK1471065T3 (da) * 2002-01-28 2008-03-25 Fuji Yakuhin Co Ltd Hidtil ukendt 1,2,4-triazolforbindelse
ATE348831T1 (de) * 2002-05-07 2007-01-15 Neurosearch As Diazabicyclische biarylderivate
AU2003250117B2 (en) * 2002-07-29 2007-05-10 F. Hoffmann-La Roche Ag Novel benzodioxoles
AR042052A1 (es) * 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
JP2006525312A (ja) 2003-04-28 2006-11-09 アブ サイエンス 脳虚血を治療するためのチロシンキナーゼ阻害剤の使用方法
US7244739B2 (en) 2003-05-14 2007-07-17 Torreypines Therapeutics, Inc. Compounds and uses thereof in modulating amyloid beta
BRPI0410905A (pt) * 2003-06-03 2006-06-27 Novartis Ag inibidores de p-38
WO2005012263A1 (en) * 2003-07-24 2005-02-10 Pharmagene Laboratories Limited 5-ht2b receptor antagonists
FR2862647B1 (fr) 2003-11-25 2008-07-04 Aventis Pharma Sa Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant
GB0401336D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
CN1942450A (zh) * 2004-02-11 2007-04-04 詹森药业有限公司 取代三唑化合物的制备方法
NZ580450A (en) * 2004-09-17 2011-06-30 Vertex Pharma Diaminotriazole Compounds Useful as Protein Kinase Inhibitors
ZA200703950B (en) 2004-10-21 2008-07-30 Vertex Pharma Triazoles useful as inhibitors of protein kinases
WO2006064375A2 (en) 2004-12-16 2006-06-22 Ab Science Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases
EP1954696B1 (en) * 2005-01-19 2011-02-23 Bristol-Myers Squibb Company 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders
JP5341516B2 (ja) * 2005-09-13 2013-11-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ２−アニリン−４−アリール置換チアゾール誘導体
JO3019B1 (ar) 2006-04-19 2016-09-05 Janssen Pharmaceutica Nv ثلاثي مستبدل 4،2،1-ثلاثي زولات
ES2424023T3 (es) * 2007-10-18 2013-09-26 Janssen Pharmaceutica N.V. 1,2,4-triazoles trisustituidos
CN102066343B (zh) * 2008-03-19 2013-12-04 詹森药业有限公司 作为烟碱乙酰胆碱受体调节剂的三取代1，2，4-三唑类
ES2392795T3 (es) 2008-04-17 2012-12-13 Proximagen Limited Indoles como moduladores del receptor nicotínico de acetilcolina de subtipo alfa-7
WO2009135944A1 (en) * 2008-05-09 2009-11-12 Janssen Pharmaceutica Nv Trisubstituted pyrazoles as acetylcholine receptor modulators
ES2446356T3 (es) * 2009-09-17 2014-03-07 Janssen Pharmaceutica N.V. N-fenil-1-(4-piridinil)-1H-pirazol-3-aminas sustituidas
JO3078B1 (ar) * 2009-11-27 2017-03-15 Janssen Pharmaceutica Nv مورفولينوثيازولات بصفتها منظمات الوستيرية نوع الفا 7 موجبة
KR101851140B1 (ko) 2011-02-25 2018-04-23 얀센 파마슈티카 엔.브이. 알파 7 nAChR의 알로스테릭 조절자로서의 (피리딘-4-일)벤질아미드

Also Published As

Publication number Publication date
TW200934491A (en) 2009-08-16
EP2205594B1 (en) 2011-08-31
AR068919A1 (es) 2009-12-16
CA2697982A1 (en) 2009-04-23
CA2697982C (en) 2015-09-22
CL2008003067A1 (es) 2009-11-27
CN101827839A (zh) 2010-09-08
PA8799901A1 (es) 2009-05-15
IL205102A (en) 2015-04-30
MX2010004176A (es) 2010-05-03
RU2476433C2 (ru) 2013-02-27
AU2008313775A1 (en) 2009-04-23
WO2009050185A1 (en) 2009-04-23
EP2205594A1 (en) 2010-07-14
AU2008313775B2 (en) 2012-12-13
RU2010119458A (ru) 2011-11-27
ES2371863T3 (es) 2012-01-10
IL205102A0 (en) 2010-11-30
ATE522523T1 (de) 2011-09-15
US8404851B2 (en) 2013-03-26
US20100240707A1 (en) 2010-09-23
JO2784B1 (en) 2014-03-15
CN101827839B (zh) 2012-10-24
JP2011500624A (ja) 2011-01-06

Similar Documents

Publication Publication Date Title
PE20091080A1 (es) 2-[3-(2,2-difluoro-benzo[1,3]dioxol-5-ilamino)-5-(2,6-dimetil-piridin-4-il)-[1,2,4]triazol-1-il]-n-etil-acetamida y sus sales como moduladores de los receptores nicotinicos alfa 7
PE20070585A1 (es) Derivados de sulfonamida como activadores de glucoquinasa
PE20080830A1 (es) Compuestos derivados de sulfonilo que modulan el receptor cb2
CO6300954A2 (es) Derivados de tienopiridinonas como activadores de proteina quinasa activados por ampk
PE20080951A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
CL2009001059A1 (es) Compuestos derivados de 1,3-oxazin-2-ona-3,6 sustituidos, inhibidores de la actividad de la 11-beta-hidroxiesteroide deshidrogenasa i; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades tales como diabetes mellitus, entre otras.
ECSP066991A (es) 3-(4-heteroarilciclohexilamino)ciclopentanocarboxamidas como moduladores de receptores de quimiocinas
PE20091724A1 (es) Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7
ECSP067120A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
PE20060937A1 (es) Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2)
PE20141375A1 (es) Activadores de glucoquinasa
PE20090248A1 (es) Moduladores de beta-amiloide
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
CO6470866A2 (es) Enantiómeros de compuestos de espirooxindol y sus usos como agentes terapéuticos.
PE20090435A1 (es) Inhibidores de tetrahidropiranocromeno de gamma secretasa
CL2008000836A1 (es) Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
CL2009000619A1 (es) Compuestos derivados de carbazol, inhibidores de la proteina hsp90; procedimiento para preparar los compuestos; compuestos intermediarios, composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en el tratamiento del cancer.
AR058807A1 (es) 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5
CO6331304A2 (es) Derivados de tienopiridonas como activadores de proteina quinasa activados por amp (ampk)
PE20140703A1 (es) Derivados de heteroarilo como moduladores de nachr alfa 7
PE20090622A1 (es) Nuevos derivados de bencimidazol sustituido
AR062471A1 (es) SESQUIHIDRATO CRISTALINO DEL TARTRATO DE 1-[2-FLUORO-4-(TRIFLUOROMETIL)-3-(3-{[4-METIL-5-(4-METIL-1, 3-OXAZOL-5-IL)-4H-1, 2, 4-TRIAZOL-3-IL]TIO}PROPIL)-3-AZABICICLO[3.1.0]HEXANO (1S, 5R) o (2R, 3R), SU USO PARA LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA MODU
CL2009000628A1 (es) Forma cristalina de 5-[3-(2,5-dicloro-4,6-dimetil-1-oxi-piridin-3-il)-[1,2,4]oxadiazol-5-il]-3-nitrobenceno-1,2-diol, composicion farmaceutica que la comprende, proceso para obtenerla y su uso para tratar trastornos del animo, enfermedad de parkinson y trastornos parkinsonianos, alteraciones gastrointestinales, entre otros.
CR10060A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas

Legal Events

Date Code Title Description
FG Grant, registration